Exploring Alternate Payment Models in Oncology

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.